Strengthening the US Response to Resistant Gonorrhea: An Overview of a Multisite Program to Enhance Local Response Capacity for Antibiotic-Resistant Neisseria gonorrhoeae.

Autor:	Schlanger K; From the Centers for Disease Control and Prevention, Atlanta GA., Learner ER; From the Centers for Disease Control and Prevention, Atlanta GA., Pham CD; From the Centers for Disease Control and Prevention, Atlanta GA., Mauk K; From the Centers for Disease Control and Prevention, Atlanta GA., Golden M; University of Washington/Public Health-Seattle & King County, Seattle, WA., Wendel KA; Denver Health, Denver, CO., Amsterdam L; Wisconsin Department of Health Services, Madison, WI., McNeil CJ, Johnson K; New York City Department of Health and Mental Hygiene, Long Island City, NY., Nguyen TQ; San Francisco Department of Public Health, San Francisco, CA., Holderman JL, Hasty GL; Hawaii Department of Health, Honolulu, HI., St Cyr SB; From the Centers for Disease Control and Prevention, Atlanta GA., Town K; From the Centers for Disease Control and Prevention, Atlanta GA., Nash EE; From the Centers for Disease Control and Prevention, Atlanta GA., Kirkcaldy RD; From the Centers for Disease Control and Prevention, Atlanta GA.
Jazyk:	angličtina
Zdroj:	Sexually transmitted diseases [Sex Transm Dis] 2021 Dec 01; Vol. 48 (12S Suppl 2), pp. S97-S103.
DOI:	10.1097/OLQ.0000000000001545
Abstrakt:	Background: In 2016, Centers for Disease Control and Prevention initiated Strengthening the US Response to Resistant Gonorrhea (SURRG) in multiple jurisdictions to enhance antibiotic resistant gonorrhea rapid detection and response infrastructure and evaluate the impact of key strategies. Methods: Eight jurisdictions were funded to establish or enhance local gonococcal culture specimen collection in sexually transmitted disease and community clinics, conduct rapid antimicrobial susceptibility testing (AST) in local laboratories, modify systems for enhanced data collection and rapid communication of results, and initiate enhanced partner services among patients with gonorrhea demonstrating elevated minimum inhibitory concentrations (MICs) to ceftriaxone, cefixime or azithromycin. Results: Grantees incorporated genital, pharyngeal, and rectal gonococcal culture collection from all genders at participating clinics. During 2018 to 2019, grantees collected 58,441 culture specimens from 46,822 patients and performed AST on 10,814 isolates (representing 6.8% [3412] and 8.9% [4883] of local reported cases in 2018 and 2019, respectively). Of isolates that underwent AST, 11% demonstrated elevated azithromycin MICs; fewer than 0.5% demonstrated elevated ceftriaxone or cefixime MICs. Among patients whose infections demonstrated elevated MICs, 81.7% were interviewed for partner elicitation; however, limited new cases were identified among partners and contacts. Conclusions: As a public health model to build capacity to slow the spread of emerging resistance, SURRG successfully expanded culture collection, implemented rapid AST, and implemented an enhanced partner services investigation approach in participating jurisdictions. Findings from SURRG may enhance preparedness efforts and inform a longer-term, comprehensive, and evidence-based public health response to emerging gonococcal resistance. Continued development of innovative approaches to address emerging resistance is needed. Competing Interests: Conflicts of Interest: None declared. (Copyright © 2021 American Sexually Transmitted Diseases Association. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu